Status:
COMPLETED
Plasma Metabolic Biomarkers for Gastric Cancer Diagnosis
Lead Sponsor:
Beijing Friendship Hospital
Conditions:
Gastric Cancer
Eligibility:
All Genders
Brief Summary
The aim of this observational study is to comprehensively analyze the metabolites in plasma samples from gastric cancer patients using advanced mass spectrometry detection technology, in conjunction w...
Detailed Description
Firstly, a wide-targeted metabolomic measurement will be conducted on plasma samples from the discovery cohort to identify potential metabolite candidate markers and construct a gastric cancer patient...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of gastric cancer or benign gastric diseases through gastroscopy and pathological examination.
- Collection of plasma samples prior to surgical treatment.
- Availability of complete clinical data.
Exclusion
- Previous reception of anti-tumor treatments (including radiotherapy, chemotherapy, etc.) before blood collection.
- Coexistence of other systemic tumors.
- Absence of plasma sample collection before surgical treatment.
- Incomplete clinical data.
- Pregnancy status.
Key Trial Info
Start Date :
October 20 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 18 2025
Estimated Enrollment :
1706 Patients enrolled
Trial Details
Trial ID
NCT06109805
Start Date
October 20 2023
End Date
February 18 2025
Last Update
February 20 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Friendship Hospital, Capital Medical University
Beijing, China
2
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China
3
Renmin Hospital of Wuhan University
Wuhan, China
4
Tongji Hospital, Tongji Medical College of HUST
Wuhan, China